Short-term therapy with celecoxib and lansoprazole modulates Th1/Th2 immune response in human gastric mucosa

Helicobacter

Volumn 15, Issue 5, 2010, Pages 449-459

  Larussa, Tiziana ^a   Suraci, Evelina ^a   Leone, Isabella ^a   Nazionale, Immacolata ^a   Abenavoli, Ludovico ^a   Galasso, Olimpio ^a   Amorosi, Andrea ^a   Imeneo, Maria ^a   Luzza, Francesco ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Celecoxib; COX 2; H. pylori; Lansoprazole; T helper 1; T helper 2

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; GAMMA INTERFERON; INTERLEUKIN 4; LANSOPRAZOLE; PROSTAGLANDIN E2; STAT6 PROTEIN; TRANSCRIPTION FACTOR T BET;

ADULT; AGED; ARTICLE; BONE PAIN; CLINICAL ARTICLE; DOWN REGULATION; DYSPEPSIA; FEMALE; GASTRITIS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION; STOMACH BIOPSY; STOMACH MUCOSA; TH1 CELL; TH2 CELL;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; CYCLOOXYGENASE 2; CYTOKINES; FEMALE; GASTRIC MUCOSA; HELICOBACTER PYLORI; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; PYRAZOLES; STAT6 TRANSCRIPTION FACTOR; SULFONAMIDES; TH1 CELLS; TH2 CELLS;

HELICOBACTER PYLORI;

EID: 77956531699     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2010.00796.x     Document Type: Article

References (33)

1. Ernst PB, Gold BD. The disease spectrum of Helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 2000 54: 615 640.
2. Wang L, Zhang X, Farrar WL, Yang X. Transcriptional crosstalk between nuclear receptors and cytokine signal transduction pathways in immunity. Cell Mol Immunol 2004 1: 416 424.
3. Mullen AC, High FA, Hutchins AS, et al. Role of T-bet in commitment of Th1 cells before IL-12-dependent selection. Science 2001 292: 1907 1910.
4. Lederer JA, Perez VL, DesRoches L, Kim SM, Abbas AK, Lichtman AH. Cytokine transcriptional events during helper T cell subset differentiation. J Exp Med 1996 184: 397 406.
5. Karttunen R, Karttunen T, Ekre HP, MacDonald TT. Interferon gamma and interleukin 4 secreting cells in the gastric antrum in Helicobacter pylori positive and negative gastritis. Gut 1995 36: 341 345.
6. D'Elios MM, Manghetti M, De Carli M, et al. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J Immunol 1997 158: 962 967.
7. Eaton KA, Mefford M, Thevenot T. The role of T cell subsets and cytokines in the pathogenesis of Helicobacter pylori gastritis in mice. J Immunol 2001 166: 7456 7461.
8. Akhiani AA, Pappo J, Kabok Z, Schon K, Gao W, Franzen LE, Lycke N. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol 2002 169: 6977 6984.
9. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, ld LJ, Screiber RD. IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001 410: 1107 1111.
10. Van Rees BP, Saukkonen K, Ristimaki A, Polkowski W, Tytgat GN, Drillenburg P, Offerhaus GJ. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol 2002 196: 171 179.
11. Pellicanò A, Imeneo M, Leone I, Larussa T, Luzza F. Enhanced activation of cyclooxygenase-2 down-regulates Th1 signaling pathway in Helicobacter pylori-infected human gastric mucosa. Helicobacter 2007 12: 193 199. (Pubitemid 46701092)
12. Ichikawa H, Yoshida N, Takagi T, et al. Lansoprazole ameliorates intestinal mucosal damage induced by ischemia-repersion in rats. World J Gastroenterol 2004 10: 2814 2817.
13. Kuroda M, Yoshida N, Ichikawa H, et al. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin rat enteritis. Int J Mol Med 2006 17: 89 93.
14. Wandall JH. Effect of omeprazole on neutrophil chemotaxis, superoxide production, degranulation, and translocation of cytochrome b-245. Gut 1992 33: 617 621.
15. Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther 2000 1: 74 81.
16. Suzuki M, Suzuki H, Kitahora T, et al. Proton pump inhibitor modifies inflammatory reaction in human gastric mucosa infected by Helicobacter pylori. Aliment Pharmacol Ther 2002 16: 229 234.
17. Graham DY, Opekun AR, Yamaoka Y, Osato MS, El-Zimaty HMT. Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment Pharmacol Ther 2003 17: 193 200.
18. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histpatology of Gastritis, Houston 1994. Am J Surg Pathol 1996 20: 1161 1181.
19. Zavros Y, Rathinavelu S, Kao JY, et al. Treatment of Helicobacter gastritis with IL-4 requires somatostatin. Proc Natl Acad Sci USA 2003 100: 12944 12949.
20. Zavros Y, Rieder G, Ferguson A, Samuelson LC, Merchant JL. Hypergastrinemia in response to gastric inflammation suppresses somatostatin. Am J Physiol Gastrointest Liver Physiol 2002 282: G175 83.
21. Ibiza S, Alvarez A, Romero W, Barrachina MD, Esplugues JV, Calatayud S. Gastrin induces the interaction between human mononuclear leukocytes and endothelial cells through the endothelial expression of P-selectin an VCAM-1. Am J Physiol Cell Physiol 2009 297: C1588 95.
22. Asonuma S, Imatani A, Asano N, et al. Helicobacter pylori induces gastric mucosal intestinal metaplasia through the inhibition of interleukin-4-mediated HMG box protein Sox2 expression. Am J Physiol Gastrointest Liver Physiol 2009 297: G312 22.
23. Scheiman JM, Greenson JK, Lee J, Cryers B. Effect of cyclooxygenase-2 inhibition on human Helicobacter pylori gastritis: mechanisms underlying gastrointestinal safety and implication for cancer prevention. Aliment Pharmacol Ther 2003 17: 1535 1543.
24. Tanikawa T, Watanabe T, Higuchi K, et al. Lansoprazole, a proton pump inhibitor, suppresses production of tumor necrosis factor-α and interleukin-1ß induced by lipopolysaccharide and Helicobacter Pylori bacterial components in humans monocytic cells via inhibition of activation of nuclear factor-κB and extracellular signal-regulated kinase. J Clin Biochem Nutr 2009 45: 86 92.
25. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995 83: 493 501.
26. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997 99: 2254 2259.
27. Hull MA, Thomson JL, Hawkey CJ. Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells. Gut 1999 45: 529 536.
28. Li GQ, Xia HH, Chen MH, et al. Effects of cyclooxygenase-1 and 2-gene disruption on Helicobacter pylori-induced gastric inflammation. J Infect Dis 2006 193: 1037 1046.
29. Nam KT, Hahm KB, Oh SY, et al. The selective cyclooxygenase-2 inhibitor nimesulide prevents Helicobacter pylori-associated gastric cancer development in a mouse model. Clin Cancer Res 2004 10: 8105 8113.
30. Logan RPH, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995 36: 12 6.
31. Suzuki M, Suzuki H, Kitahora T, et al. Treatment with a proton pump inhibitor promotes corpus gastritis in patients with H. pylori-infected antrum-predominant gastritis. Aliment Pharmacol Ther 2002 16: 159 165.
32. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori and the development of gastric cancer. N Engl J Med 2001 345: 784 789.
33. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996 334: 1018 1022.